Publikationen im NUM
Hier finden Sie eine Liste der Publikationen, die im Zusammenhang mit dem Netzwerk Universitätsmedizin in der ersten und zweiten Förderphase entstanden sind.
I. M. Veer,
A. Riepenhausen,
M. Zerban,
C. Wackerhagen,
L. M. C. Puhlmann,
H. Engen,
G. Köber,
S. A. Bögemann,
J. Weermeijer,
A. Uściłko,
N. Mor,
M. A. Marciniak,
A. D. Askelund,
A. Al-Kamel,
S. Ayash,
G. Barsuola,
V. Bartkute-Norkuniene,
S. Battaglia,
Y. Bobko and
others,
"Psycho-social factors associated with mental resilience in the Corona lockdown",
Translational Psychiatry,
vol. 11,
no. 1,
pp. 1—11,
2021.
| DOI: | 10.1038/s41398-020-01150-4 |
| Datei: | https://doi.org/10.1038/s41398-020-01150-4 |
E. Morawa,
C. Schug,
F. Geiser,
P. Beschoner,
L. Jerg-Bretzke,
C. Albus,
K. Weidner,
N. Hiebel,
A. Borho and
Y. Erim,
"Psychosocial burden and working conditions during the COVID-19 pandemic in Germany: The VOICE survey among 3678 health care workers in hospitals",
Journal of Psychosomatic Research,
vol. 144,
pp. 110415,
2021.
| DOI: | 10.1016/j.jpsychores.2021.110415 |
L. Jerg-Bretzke,
M. Kempf,
M. N. Jarczok,
K. Weimer,
C. Hirning,
H. Gündel,
Y. Erim,
E. Morawa,
F. Geiser,
N. Hiebel,
K. Weidner,
C. Albus and
P. Beschoner,
"Psychosocial Impact of the COVID-19 Pandemic on Healthcare Workers and Initial Areas of Action for Intervention and Prevention—The egePan/VOICE Study",
International Journal of Environmental Research and Public Health,
vol. 18,
no. 19,
pp. 10531,
2021.
| DOI: | 10.3390/ijerph181910531 |
G. Anton,
A. Kuehn-Steven,
M. K. Taucher,
I. Bernemann and
T. Illig,
"Quality management in times of COVID-19: Remote audits as tool to assess sample quality for NAPKON.",
European Biobank Week 2021,
2021.
A. Bucher,
J. Kleesiek,
C. K. Kuhl,
G. Antoch and
others,
"RACOON: A nationwide radiological infrastructure of German University Radiologies for collaborative imaging research on COVID-19",
Conference of the Radiological Society of North America,
2021.
A. Denzler,
M. L. Jacobs,
V. Witte and
et al,
"Rapid comparative evaluation of SARS-CoV-2 rapid point-of-care antigen tests",
MedRxiv,
2021.
| DOI: | 10.1101/2021.07.29.21261314 |
| Datei: | https://doi.org/10.1101/2021.07.29.21261314 |
S. Kluge,
J. J. Malin,
F. Fichtner,
O. J. Müller,
N. Skoetz and
C. Karagiannidis,
"Recommendations on the In-Hospital Treatment of Patients With COVID-19",
Dtsch Arztebl Int,
2021.
| DOI: | 10.3238/arztebl.m2021.0374 |
K. I. Wagner and
et al,
"Recruitment of highly cytotoxic CD8+ T cell receptors in mild SARS-CoV-2 infection",
Cell reports,
vol. 35,
pp. 110214,
2021.
| DOI: | 10.1016/j.celrep.2021.110214 |
S. Bauer,
S. Contreras,
J. Dehning,
M. Linden,
E. Iftekhar,
S. B. Mohr,
A. Olivera-Nappa and
V. Priesemann,
"Relaxing restrictions at the pace of vaccination increases freedom and guards against further COVID-19 waves",
PLOS Computational Biology,
vol. 17,
no. 9,
pp. e1009288,
2021.
| DOI: | 10.1371/journal.pcbi.1009288 |
D. Thole,
T. Ole Diesterhöft,
S. Vogel,
M. Greve,
E. Bauer,
S. Strathmann,
C. Elsner,
N. Kolbe and
D. Krefting,
"Relevant Aspects for Sustainable Open Source Pandemic Apps and Platform Deployment with Focus on Community Building",
Stud Health Technol Inform,
vol. 283,
pp. 186—193,
2021.
| DOI: | 10.3233/SHTI210580 |
K. Ansems,
F. Grundeis,
K. Dahms,
A. Mikolajewska,
V. Thieme,
V. Piechotta,
M. Metzendorf,
M. Stegemann,
C. Benstoem and
F. Fichtner,
"Remdesivir for the treatment of COVID‐19",
Cochrane Database of Systematic Reviews,
vol. 2021,
no. 8,
pp. CD014962,
2021.
| DOI: | 10.1002/14651858.CD014962 |
D. Wurzer,
P. Spielhagen,
A. Siegmann,
A. Gercekcioglu,
J. Gorgass,
S. Henze,
Y. Kolar,
F. Koneberg,
S. Kukkonen,
H. McGowan,
S. Schmid-Eisinger,
A. Steger,
M. Dommasch,
H. U. Haase,
A. Müller,
E. Martens,
B. Haller,
K. M. Huster and
G. Schmidt,
"Remote monitoring of COVID-19 positive high-risk patients in domestic isolation: A feasibility study",
PLOS ONE,
vol. 16,
no. 9,
pp. e0257095,
2021.
| DOI: | 10.1371/journal.pone.0257095 |
| Datei: | https://doi.org/10.1371/journal.pone.0257095 |
S. Graf,
L. Engelmann,
O. Wölfler and
others,
"Reopening the Bavarian State Opera Safely: Hygiene Strategies and Incidence of COVID-19 in Artistic Staff During Theater Season 2020/2021",
Journal of Voice,
2021.
| DOI: | 10.1016/j.jvoice.2021.11.012 |
| Datei: | https://doi.org/10.1016/j.jvoice.2021.11.012 |
M. Salholz-Hillel,
P. Grabitz,
M. Pugh-Jones,
D. Strech and
N. J. DeVito,
"Results availability and timeliness of registered COVID-19 clinical trials: interim cross-sectional results from the DIRECCT study",
BMJ Open,
vol. 11,
no. 11,
pp. e053096,
2021.
| DOI: | 10.1136/bmjopen-2021-053096 |
F. Nordsiek,
E. Bodenschatz,
G. Bagheri and
et al,
"Risk assessment for airborne disease transmission by poly-pathogen aerosols",
PLOS ONE,
2021.
| DOI: | 10.1371/journal.pone.0248004 |
M. Wunsch,
D. Aschemeier,
E. Hegera and
et al,
"Safe and effective pool testing for SARS-CoV-2 detection",
J Clin Virol,
vol. 145,
2021.
| DOI: | 10.1016/j.jcv.2021.105018 |
S. Reis,
M. Popp,
B. Schmid,
M. Stegemann,
M. Metzendorf,
P. Kranke,
P. Meybohm and
S. Weibel,
"Safety and Efficacy of Intermediate- and Therapeutic-Dose Anticoagulation for Hospitalised Patients with COVID-19: A Systematic Review and Meta-Analysis",
J Clin Med,
vol. 11,
no. 1,
pp. 57,
2021.
| DOI: | 10.3390/jcm11010057 |
D. Hillus and
et al,
"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study",
The Lancet Respiratory Medicine,
2021.
| DOI: | 10.1016/S2213-2600(21)00357-X |
M. Möckel,
V. M. Corman,
M. S. Stegemann and
et al,
"SARS-CoV-2 antigen rapid immunoassay for diagnosis of COVID-19 in the emergency department",
Biomarker,
vol. 26,
no. 3,
2021.
| DOI: | 10.1080/1354750X.2021.1876769 |
S. Deinhardt-Emmer,
S. Bottcher,
C. Haring,
L. Giebeler,
A. Henke and
e. a. Zell,
"SARS-CoV-2 causes severe epithelial inflammation and barrier dysfunction",
J Virol,
2021.
D. Wendisch,
O. Dietrich,
T. Mari,
S. Stillfried,
I. Ibarra,
M. Mittermaier,
C. Mache,
R. Chua,
R. Knoll,
S. Timm and
others,
"SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis",
Cell,
vol. 184,
no. 26,
pp. 6243—6261.e27,
2021.
| DOI: | 10.1016/j.cell.2021.11.033 |
D. Wendisch,
O. Dietrich,
T. Mari,
S. Stillfried,
I. L. Ibarra and
e. a. Mittermaier,
"SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis",
Cell,
vol. 184,
pp. 6243—6261.e6227,
2021.
| DOI: | 10.1016/j.cell.2021.11.033 |
D. Wendisch and
et al,
"SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis",
Cell,
vol. 184,
pp. 6243-6261.e27,
2021.
| DOI: | 10.1016/j.cell.2021.11.033 |
D. Wendisch,
O. Dietrich,
T. Mari and
et al,
"SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis",
Cell,
2021.
| DOI: | 10.1016/j.cell.2021.11.033 |
D. Wendisch,
O. Dietrich,
T. Mari,
S. Von Stillfried,
I. Ibarra,
M. Mittermaier,
C. Mache,
R. Chua,
R. Knoll,
S. Timm,
S. Brumhard,
T. Kramer,
R. Mothes,
R. Bülow,
J. Schulze,
S. Djudjaj,
F. Pott,
J. Kazmierski,
J. Radke,
S. Baßler,
B. Conrad,
M. Landthaler,
E. Wyler,
D. Horst,
S. Hippenstiel,
A. Hocke,
F. Heppner,
A. Uhrig,
C. V. García,
S. Herold,
S. Elezkurtaj,
C. Thibeault,
M. Witzenrath,
N. Suttorp,
C. Drosten,
C. Goffinet,
F. Kurth,
J. L. Schultze,
H. Radbruch,
M. Ochs,
R. Eils,
H. C. Müller-Redetzky,
A. E. Hauser,
C. Conrad,
T. Wolff,
P. Boor,
L. E. Sander,
H. Zauber,
A. Hiller,
A. Pascual-Reguant,
A. Leipold,
F. Erhard,
R. Geffers,
P. Pergantis,
A. Aschenbrenner,
B. Sawitzki,
D. C. O. I. (.,
C. Cochain,
M. Luecken,
F. Theis,
M. Selbach,
A. Saliba and
F. Machleidt,
"SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis.",
Cell. 2021;184(26):6243-6261.e27.,
2021.
J. Jansen,
K. Reimer,
J. Nagai and
et al,
"SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids",
Cell Stem Cell,
2021.
| DOI: | 10.1016/j.stem.2021.12.010 |
M. Hoffmann and
et al,
"SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization",
Cell Reports,
vol. 35,
pp. 109017,
2021.
| DOI: | 10.1016/j.celrep.2021.109017 |
J. J. Malin and
et al,
"SARS-CoV-2 neutralizing antibody treatment in COVID-19 patients with immunodeficiency due to B-cell non-Hodgkin lymphoma",
Blood advances,
2021.
| DOI: | 10.1182/bloodadvances.2021006655 |
T. Schwarz and
et al,
"SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients",
Frontiers in immunology,
vol. 12,
pp. 629185,
2021.
| DOI: | 10.3389/fimmu.2021.629185 |
S. Stillfried,
S. Villwock,
R. D. Bülow,
S. Djudjaj,
E. M. Buhl,
A. Maurer,
N. Ortiz-Brüchle,
P. Celec,
B. M. Klinkhammer,
D. W. Wong,
C. Cacchi,
T. Braunschweig,
R. Knüchel-Clarke,
E. Dahl and
P. Boor,
"SARS-CoV-2 RNA screening in routine pathology specimens",
Microb Biotechnol,
vol. 14,
no. 4,
pp. 1627-1641,
Jul.
2021.
| DOI: | 10.1111/1751-7915.13828 |
S. Heinemann,
A. Bludau,
H. Kaba and
et al,
"SARS-CoV-2 surveillance and testing: results of a survey from the Network of University Hospitals (NUM), B-FAST",
GMS Hyg Infect Control,
vol. 16,
2021.
| DOI: | 10.3205/dgkh000402 |
S. Heinemann,
A. Bludau,
H. Kaba,
P. Knolle,
H. Grundmann and
S. Scheithauer,
"SARS-CoV-2 surveillance and testing: results of a survey from the Network of University Hospitals (NUM), B-FAST",
GMS hygiene and infection control,
vol. 16,
pp. Doc31,
2021.
Abstract:
Background: The B-FAST project of the National University Network (NUM) examines and records applied surveillance strategies implemented in hospitals i.a., to protect patients and employees from SARS-CoV-2 infection. Methods: Infection control physicians in German university hospitals (UK), as well as non-university hospitals (NUK; Bavaria, Lower Saxony) were surveyed in March 2021 regarding SARS-CoV-2 testing/surveillance strategies in a cross-sectional study using a standardized online questionnaire. The focus was on screening strategies taking into account the \textquotedbltest\textquotedbl methods used (case history, PCR, antigen, antibody test). Results: The response rate was 91.7% (33/36) in UK and 11.3%-32.2% in NUK. Almost all hospitals (95.0%) performed a symptom and exposure check and/or testing upon inpatient admission. Non-cause-related testing (screening) of health care workers in COVID wards was preferably done by PCR in UK (69.7% PCR; 12.1% antigen), while NUK (29.9% PCR; 49.3% antigen) used antigen testing more frequently. Regardless of the type of facility, about half of the respondents rated the benefit of screening higher than the effort (patients: 49%; employees: 45%). Conclusion: Testing/surveillance strategies find a high level of acceptance at German hospitals and are generally carried out in accordance with the national testing strategy with differences depending on the level of care. Hintergrund: Im „Bundesweiten Forschungsnetzwerk zur Angewandten Surveillance und Testung“ (B-FAST) werden anwendungsbezogene Strategien geprüft und erfasst, die u.a. in Krankenhäusern zum Schutz von Patient*innen und Beschäftigten vor SARS-CoV-2 implementiert wurden.Methoden: Im März 2021 wurden in einer Querschnittstudie mit einem standardisierten Online-Fragebogen die leitenden (Krankenhaus-)Hygieniker*innen in deutschen Universitätskliniken (UK), sowie Nicht-Universitätskliniken (NUK) in Bayern und Niedersachsen zu SARS-CoV-2 Test- und Surveillance-Strategien befragt. Im Fokus standen Screening-Strategien unter Berücksichtigung der eingesetzten „Test“-Methoden (Anamnese, PCR-, Antigen-, Antikörpertest).Ergebnisse: Der Rücklauf liegt bei 91,7% (33 von 36) aus den UK, bei 32,2% (37 von 115) aus den niedersächsischen NUK und bei 11,3% (30 von 265) aus den bayrischen NUK. Nahezu alle Kliniken (95,0%) führen bei der Aufnahme stationärer Patient*innen einen Symptom/Expositionscheck und/oder eine Testung durch. Das nicht-anlassbezogene Testen (Screening) von Beschäftigten im COVID-Bereich erfolgte in UK (69,7% PCR; 12,1% Antigen) bevorzugt durch PCR, während NUK (29,9% PCR; 49,3% Antigen) häufiger Antigentests einsetzten. Unabhängig von der Einrichtungsart bewerten etwa die Hälfte der Befragten den Nutzen von Screening höher als den Aufwand (bei Patient*innen 49,0%; bei Beschäftigten 45,0%).Fazit: Test- und Surveillance-Strategien finden an deutschen Kliniken hohe Akzeptanz und werden grundsätzlich in Anlehnung an die nationale Teststrategie — mit Unterschieden je nach Versorgungsstufe — durchgeführt.
| DOI: | 10.3205/dgkh000402 |
Abstract:
Background: The B-FAST project of the National University Network (NUM) examines and records applied surveillance strategies implemented in hospitals i.a., to protect patients and employees from SARS-CoV-2 infection. Methods: Infection control physicians in German university hospitals (UK), as well as non-university hospitals (NUK; Bavaria, Lower Saxony) were surveyed in March 2021 regarding SARS-CoV-2 testing/surveillance strategies in a cross-sectional study using a standardized online questionnaire. The focus was on screening strategies taking into account the \textquotedbltest\textquotedbl methods used (case history, PCR, antigen, antibody test). Results: The response rate was 91.7% (33/36) in UK and 11.3%-32.2% in NUK. Almost all hospitals (95.0%) performed a symptom and exposure check and/or testing upon inpatient admission. Non-cause-related testing (screening) of health care workers in COVID wards was preferably done by PCR in UK (69.7% PCR; 12.1% antigen), while NUK (29.9% PCR; 49.3% antigen) used antigen testing more frequently. Regardless of the type of facility, about half of the respondents rated the benefit of screening higher than the effort (patients: 49%; employees: 45%). Conclusion: Testing/surveillance strategies find a high level of acceptance at German hospitals and are generally carried out in accordance with the national testing strategy with differences depending on the level of care. Hintergrund: Im „Bundesweiten Forschungsnetzwerk zur Angewandten Surveillance und Testung“ (B-FAST) werden anwendungsbezogene Strategien geprüft und erfasst, die u.a. in Krankenhäusern zum Schutz von Patient*innen und Beschäftigten vor SARS-CoV-2 implementiert wurden.Methoden: Im März 2021 wurden in einer Querschnittstudie mit einem standardisierten Online-Fragebogen die leitenden (Krankenhaus-)Hygieniker*innen in deutschen Universitätskliniken (UK), sowie Nicht-Universitätskliniken (NUK) in Bayern und Niedersachsen zu SARS-CoV-2 Test- und Surveillance-Strategien befragt. Im Fokus standen Screening-Strategien unter Berücksichtigung der eingesetzten „Test“-Methoden (Anamnese, PCR-, Antigen-, Antikörpertest).Ergebnisse: Der Rücklauf liegt bei 91,7% (33 von 36) aus den UK, bei 32,2% (37 von 115) aus den niedersächsischen NUK und bei 11,3% (30 von 265) aus den bayrischen NUK. Nahezu alle Kliniken (95,0%) führen bei der Aufnahme stationärer Patient*innen einen Symptom/Expositionscheck und/oder eine Testung durch. Das nicht-anlassbezogene Testen (Screening) von Beschäftigten im COVID-Bereich erfolgte in UK (69,7% PCR; 12,1% Antigen) bevorzugt durch PCR, während NUK (29,9% PCR; 49,3% Antigen) häufiger Antigentests einsetzten. Unabhängig von der Einrichtungsart bewerten etwa die Hälfte der Befragten den Nutzen von Screening höher als den Aufwand (bei Patient*innen 49,0%; bei Beschäftigten 45,0%).Fazit: Test- und Surveillance-Strategien finden an deutschen Kliniken hohe Akzeptanz und werden grundsätzlich in Anlehnung an die nationale Teststrategie — mit Unterschieden je nach Versorgungsstufe — durchgeführt.
M. Hoffmann and
et al,
"SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination",
Cell Reports,
vol. 36,
pp. 109415,
2021.
| DOI: | 10.1016/j.celrep.2021.109415 |
M. Hoffmann and
et al,
"SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies",
Cell,
vol. 184,
pp. 2384-2393.e12,
2021.
| DOI: | 10.1016/j.cell.2021.03.036 |
L. Lohner,
D. Fröb,
C. Edler,
A. S. Schröder,
E. Dietz and
B. Ondruschka,
"SARS-CoV-2-assoziierte Todesfälle von erwachsenen Personen bis 50 Jahre: Eine retrospektive Auswertung der COVID-19-assoziierten Todesfälle im Jahr 2020 im Institut für Rechtsmedizin Hamburg, Deutschland [SARS-CoV-2-associated deaths in adult persons up to 50 years of age]",
Rechtsmedizin (Berl),
pp. 1-9,
2021.
N. Gassen,
J. Papies,
T. Bajaj,
J. Emanuel,
F. Dethloff and
e. a. Chua,
"SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals",
Nat Commun,
vol. 12,
pp. 3818,
2021.
N. Kreuzberger and
et al,
"SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19",
Cochrane Database of Systematic Reviews,
vol. 9,
pp. CD013825,
2021.
| DOI: | 10.1002/14651858.CD013825.pub2 |
N. Kreuzberger,
C. Hirsch,
K. L. Chai,
E. Tomlinson,
Z. Khosravi,
M. Popp,
M. Neidhardt,
V. Piechotta,
S. Salomon,
S. J. Valk,
I. Monsef,
C. Schmaderer,
E. M. Wood,
C. So-Osman,
D. J. Roberts,
Z. McQuilten,
L. J. Estcourt and
N. Skoetz,
"SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19",
Cochrane Database Syst Rev,
vol. 9,
no. 9,
pp. CD013825,
2021.
| DOI: | 10.1002/14651858.CD013825.pub2 |
C. Hirsch and
et al,
"SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19",
Cochrane Database of Systematic Reviews,
2021.
| DOI: | 10.1002/14651858.CD014945 |
K. G. Schmidt and
et al,
"SARS-CoV-2-Seronegative Subjects Target CTL Epitopes in the SARS-CoV-2 Nucleoprotein Cross-Reactive to Common Cold Coronaviruses",
Frontiers in immunology,
vol. 12,
pp. 627568,
2021.
| DOI: | 10.3389/fimmu.2021.627568 |
D. Gornyk and
et al,
"SARS-CoV-2-Seroprävalenz in Deutschland. Eine bevölkerungsbezogene sequenzielle Studie in sieben Regionen",
Dtsch Arztebl Int,
vol. 118,
pp. 824–831,
2021.
A. Klein,
F. Langenwalder,
F. Heinrich,
K. Meißner,
A. S. Schröder,
K. Püschel,
B. Ondruschka,
M. Lütgehetmann and
A. Heinemann,
"SARS-CoV2-Zufallsentdeckungen bei Hamburger Todesfällen: ein epidemiologisches Monitoring während des dynamischen Infektionsgeschehens im Frühjahr 2020 [SARS-CoV2 incidental findings among Hamburg deaths: an epidemiological monitoring during the dynamic infection event in spring 2020]",
Rechtsmedizin (Berl),
pp. 1-7,
2021.
E. R. Adams,
D. Wolday,
C. M. Denkinger and
et al,
"Scaled testing for COVID-19 needs community involvement",
J Glob Health,
vol. 11,
2021.
| DOI: | 10.7189/jogh.11.03033 |
| Datei: | https://doi.org/10.7189/jogh.11.03033 |
S. Würstle,
C. D. Spinner,
F. Voit and
et al,
"Self-sampling versus health care professional-guided swab collection for SARS-CoV-2 testing",
Infection,
vol. 49,
no. 5,
2021.
| DOI: | 10.1007/s15010-021-01614-9 |
S. Würstle,
C. Spinner,
F. Voit and
others,
"Self-sampling versus health care professional-guided swab collection for SARS-CoV-2 testing",
Infection,
vol. 49,
no. 5,
2021.
| DOI: | 10.1007/s15010-021-01614-9 |
| Datei: | https://doi.org/10.1007/s15010-021-01614-9 |
J. Schmuck,
N. Hiebel,
M. Rabe,
J. Schneider,
Y. Erim,
E. Morawa,
L. Jerg-Bretzke,
P. Beschoner,
C. Albus,
J. Hannemann,
K. Weidner,
S. Steudte-Schmiedgen,
L. Radbruch,
H. Brunsch and
F. Geiser,
"Sense of coherence, social support and religiosity as resources for medical personnel during the COVID-19 pandemic: A web-based survey among 4324 health care workers within the German Network University Medicine",
PLOS ONE,
vol. 16,
no. 7,
2021.
| DOI: | 10.1371/journal.pone.0255211 |
F. Steinbeis,
C. Thibeault,
F. Doellinger,
R. Ring,
M. Mittermaier,
C. Ruwwe-Glösenkamp,
F. Alius,
P. Knape,
H. Meyer,
L. Lippert and
others,
"Severity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-CoV-2: An observational longitudinal study over 12 months",
Respir Med,
vol. 191,
pp. 106709,
2021.
| DOI: | 10.1016/j.rmed.2021.106709 |
F. Günl,
A. Mecate-Zambrano,
S. Rehländer,
S. Hinse,
S. Ludwig and
L. Brunotte,
"Shooting at a Moving Target-Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development",
Vaccines (Basel),
vol. 9,
2021.
J. Holz,
"Singapurs gebrochenes Versprechen",
Südostasien. Zeitschrift für Politik, Kultur, Dialog,
Feb.
2021.
D. S. Fischer and
et al,
"Single-cell RNA sequencing reveals ex vivo signatures of SARS-CoV-2-reactive T cells through 'reverse phenotyping'",
Nature Communications,
vol. 12,
pp. 4515,
2021.
| DOI: | 10.1038/s41467-021-24730-4 |